Ten years experience with oral immunosuppressive treatment in adult patients with atopic dermatitis in two academic centres.
BACKGROUND
There is a lack of information on the use oral immunosuppressive drugs in atopic dermatitis (AD) daily practice.


OBJECTIVE
A 10-years overview of the use of oral immunosuppressive drugs in patients with severe AD.


METHODS
Medical charts of patients with AD, who received oral immunosuppressive drugs at the Academic Medical Center Amsterdam and in the University Medical Center Utrecht between January 2001 and January 2011, were analysed. Particular attention was paid to patient characteristics, prior treatment, prescribed oral immunosuppressive drugs, the order of use, doses and treatment durations and reasons for discontinuation of treatment.


RESULTS
Of 334 patients [53% male, mean age at start of an oral immunosuppressive drug 36.9 years (SD 13.6)] with AD received oral immunosuppressive treatment of which 102 (31%) participated in clinical trials. Cyclosporine A (CyA) was given in 80% of the patients, mycophenolate mofetil or enteric-coated mycophenolate (MMF/EC-MPS) in 31%, azathioprine (AZA) in 14%, methotrexate (MTX) in 11%, systemic glucocorticosteroids in 7% and systemic tacrolimus in 5%. In these academic centra, CyA was the first choice oral immunosuppressive in 252 patients. Reasons for discontinuation of oral immunosuppressive drugs were controlled AD disease, ineffectiveness and adverse events.


CONCLUSIONS
Various types of oral immunosuppressive drugs have been used over the past 10 years for the treatment of severe AD with a prominent first choice for CyA. Adverse events and ineffectiveness were frequent reasons for discontinuation. A prospective database of patients using oral immunosuppressive treatments in daily practice will give more insight in the effectiveness and safety and may help to formulate future recommendations.
Department of Dermatology, Academic Medical Center Amsterdam, The Netherlands.|Department of Dermatology, University Medical Center Utrecht, The Netherlands.
F M
FM
Garritsen
Department of Dermatology, Academic Medical Center Amsterdam, The Netherlands.
E
E
Roekevisch
Department of Dermatology, University Medical Center Utrecht, The Netherlands.
J
J
van der Schaft
Department of Dermatology, University Medical Center Utrecht, The Netherlands.
J
J
Deinum
Department of Dermatology, Academic Medical Center Amsterdam, The Netherlands.
P I
PI
Spuls
Department of Dermatology, University Medical Center Utrecht, The Netherlands.
M S
MS
de Bruin-Weller
D000046:Academic Medical Centers; D000284:Administration, Oral; D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use; D055815:Young Adult
D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid; D001379:Azathioprine; D016559:Tacrolimus; D008727:Methotrexate